Genomoncology

GenomOncology (GO) is a precision oncology intelligence platform founded in 2012 with a mission to transform complex, fragmented oncology data into actionable clinical decisions. Serving over 50 leading healthcare institutions — including NCI- and NCCN-designated providers and nationally recognized molecular labs — GenomOncology provides purpose-built software solutions for molecular pathologists, clinical oncologists, bioinformaticians, and researchers. The platform embeds seamlessly into existing workflows, enabling labs, clinicians, and research teams to make faster, more confident decisions in the pursuit of personalized cancer care.

The precision oncology landscape presents enormous challenges: more than 1,400 FDA-approved therapy indications and over 15,000 active clinical trials create a decision environment where fragmented data systems, manual processes, and operational bottlenecks can delay or compromise patient care. GenomOncology addresses these challenges by unifying assay and lab data, automating workflows, and delivering transparent, explainable AI-driven decision support — all within a configurable, scalable infrastructure designed to grow with the evolving demands of precision medicine.

Core Platform Capabilities

• Molecular Pathology Workbench: Designed for molecular pathologists and lab technicians, this solution accelerates reporting, eliminates bottlenecks, and merges all assay and lab data into a single, comprehensive report with automated and tailored lab workflows.
• Clinical Trial Optimization: Built for oncologists and clinical trial professionals, this module delivers real-time, seamless clinical trial matching to ensure patients are never missed for relevant trial opportunities. GenomOncology's matching capabilities are described as unparalleled in breadth and accuracy.
• Data Enablement (igniteIQ): Launched in 2020, this platform is designed for bioinformaticians and clinical researchers, enabling automated extraction and normalization of oncology data and unlocking the power of institutional data for research and translational insights.
• AI-Enhanced Decision Support: The platform delivers white-box, explainable AI directly within existing oncology workflows, supporting therapy selection, molecular reporting, and trial matching with trusted, auditable intelligence. AI-enhanced capabilities were further advanced in 2025, alongside BioMCP integration.

Platform Design Principles

• Purpose-Built for Oncology: Every component is designed specifically to handle the complexity of oncology data, including somatic and germline genomic insights, and is tailored for clinicians, labs, and researchers.
• Unified, Integrated Data Environment: Diverse data types — including EHR, lab, trial, and research data — are integrated and structured into a single, queryable environment, eliminating silos and enabling comprehensive patient views.
• Embedded, Transparent Intelligence: Decision support is delivered in real time within existing workflows, with explainable, auditable AI that avoids black-box algorithms.
• Configurable and Modular: The platform is highly adaptable to fit institutional workflows, data environments, and infrastructure needs — not a one-size-fits-all commodity solution.
• Scalable, Future-Ready Infrastructure: Built to scale and adapt alongside next-generation AI models, new data types, and the shifting precision oncology landscape.
• Flexible Deployment: The platform is designed to install anywhere, supporting diverse institutional environments.

Compliance and Accreditation

• HIPAA Compliant: Full compliance for all data handling, storage, and transmission.
• CAP/CLIA Support: Platform designed to support laboratory accreditation workflows.
• GDPR Compliant: Meets European data protection regulation requirements.
• 21 CFR Part 11 Ready: Supports electronic records and signatures for regulated laboratory environments.

Proven Real-World Impact

• 96 patients received a treatment change based on GenomOncology recommendations.
• 56 new referrals to Meditech clinical trials generated in less than six months.
• Implementation completed in as few as three weeks.
• 36% improvement in clinician satisfaction reported by customers.
• Strategic partnerships include OHSU Knight Diagnostics Lab and WeTrials, focused on accelerating patient access to precision oncology clinical trials, including for CNS cancer patients.
• Frederick Health's Vice President and CIO, Jackie Rice, cited GenomOncology as "a differentiator in the healthcare market" that has empowered clinicians with enhanced decision support capabilities.

Company Milestones and Partnerships

• Founded in 2012 with a vision to create the "operating system" for precision oncology.
• First customer go-live for pathology reporting in 2014; clinical trial matching capabilities launched in 2016.
• Expanded to 20+ customer institutions by 2018; igniteIQ data enablement platform launched in 2020.
• Surpassed 50 customer institutions and completed a Series B funding round in 2023.
• Strategic partnerships with major health systems established in 2022, with continued expansion through 2025.

GenomOncology's values — purposeful agility, transparency, outcome-driven engineering, seamless integration, and shared mission with customers — underpin its approach as a long-term partner to healthcare institutions. With over 13 years of experience enabling precision medicine, GenomOncology continues to serve as the trusted infrastructure layer for oncology's most critical decisions, making precision care scalable and practical for every institution and patient.